WAYNE, Pa. - Teleflex Incorporated (NYSE:TFX), a global provider of medical technologies, has announced the FDA clearance and full market release of its UroLift 2 System with Advanced Tissue Control (ATC) feature. This latest innovation is aimed at enhancing the treatment of benign prostatic hyperplasia (BPH) symptoms for men with all prostate types up to 100g.
The UroLift 2 System is recognized as a leading minimally invasive solution for BPH, offering an effective alternative to medications and major surgery. The addition of the ATC feature is designed to allow physicians to customize treatments to each patient's unique anatomy, aiming to maximize treatment effectiveness.
The UroLift 2 ATC System is engineered to deliver precise implant delivery and tissue manipulation through new tissue control wings and laser-etched needle markers. It also introduces a streamlined delivery system for increased physician comfort and efficiency during procedures.
Jake Newman, President of The Americas at Teleflex, highlighted the system's ability to optimize enlarged prostate treatment by providing urologists with confidence and customization capabilities. Brian Wilkins, Vice President of Research and Development for Teleflex Interventional Urology, emphasized that the UroLift 2 ATC maintains the proven effectiveness of the original system while offering significant enhancements.
Clinicians have already endorsed the new system. Dr. Adam Craig Thomas from Parkview Physicians Group Urology and Dr. Mark Pe from Genesis Urology have both praised the UroLift 2 ATC for its precision and ability to treat a broad spectrum of patients.
The UroLift System has been used to treat 475,000 men worldwide and is recommended in the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines for BPH treatment. It has been shown to not cause new onset, sustained erectile or ejaculatory dysfunction while demonstrating durability with a low retreatment rate over five years.
The information reported is based on a press release statement from Teleflex Incorporated.
InvestingPro Insights
As Teleflex Incorporated (NYSE:TFX) launches its groundbreaking UroLift 2 System with Advanced Tissue Control, the company's financial health remains robust, according to recent data from InvestingPro. The market cap of Teleflex stands at a solid 10.5 billion USD, reflecting investor confidence in the company's market position and growth potential. With a P/E ratio of 29.42 and an adjusted P/E ratio for the last twelve months as of Q4 2023 at 29.69, Teleflex is valued by the market for its earnings relative to its share price, which can be a sign of investor trust in the company's profitability.
The company's revenue growth is also notable, with a 6.57% increase over the last twelve months as of Q4 2023, indicating an upward trajectory in Teleflex's financial performance. This growth is particularly relevant as the company continues to innovate and expand its medical technology offerings, such as the UroLift 2 System. Moreover, Teleflex's solid gross profit margin of 55.37% over the same period demonstrates its ability to manage costs effectively while generating significant income from its sales.
From an investment standpoint, two InvestingPro Tips highlight the company's stability and reliability. Teleflex has maintained dividend payments for 48 consecutive years, showcasing a commitment to returning value to shareholders. Additionally, the stock generally trades with low price volatility, suggesting that it could be a potentially stable addition to an investment portfolio.
For investors interested in a deeper analysis, InvestingPro offers additional insights and metrics, including 5 more InvestingPro Tips for Teleflex. These can provide a more granular view of the company's financial health and future prospects. To take advantage of these valuable insights, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
The company's next earnings date is set for April 25, 2024, which will provide further clarity on its financial trajectory and the impact of new product releases like the UroLift 2 System on its overall performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.